ReviewPharmacoEconomics2025
Bayesian Cost-Effectiveness Analysis Using Individual-Level Data is Sensitive to the Choice of Uniform Priors on the Standard Deviations for Costs in Log-Normal Models.
Review in PharmacoEconomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundBayesian cost-effectiveness analysis (CEA) requires the specification of prior distributions for all parameters to be empirically estimated via Bayes' rule. When costs are modelled via Log-Normal distributions, Uniform prior distributions are commonly applied on the logarithm-scale standard deviations for costs due to the ease of implementation. However, the consequences of placing wide Uniform priors on standard deviations of log costs for the interpretation of original-scale CEA results remain unclear. The purpose of our study is to explore the impact of using Uniform priors for the standard deviations of cost data on CEA conclusions when costs are assumed to be log-normally distributed.
methodsThe analysis has been performed using individual-level cost-utility data from a randomised controlled trial. Costs are initially jointly modelled with quality-adjusted life years (QALYs) using Log-Normal and Beta distributions, respectively. Uniform prior distributions with different upper bounds are applied to log-scale standard deviations in the cost Log-Normal model. We compare the performance of Uniform priors under the Log-Normal distribution with other distributional assumptions for costs. A simulation study has then been conducted to explore the impact of these models and prior choices on cost estimates in CEAs.
resultsResults show that the choice of Uniform priors on standard deviations of log costs in a Log-Normal model can substantially induce large fluctuations in cost estimates, and thus potentially affect the final estimates of the intervention being cost-effective compared with other distributional assumptions. This is potentially driven by the occurrence of zero values in cost data.
conclusionBayesian CEAs may be sensitive to the choice of upper bounds of the Uniform priors for the standard deviations of log costs in Log-Normal models, particularly when data contain zero values. Our results suggest that caution should be taken when Uniform distributions with large upper bounds are used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.